Company Overview of Gamida Cell Ltd.
Gamida Cell Ltd. develops stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The company offers its products for treating a range of conditions, including blood cancers, such as leukemia, lymphoma, and solid tumors; autoimmune diseases; and non-malignant hematological diseases, such as sickle cell disease and thalassemia, neutropenia, acute radiation syndrome, and metabolic diseases. Its products include StemEx, a stem cell therapy product that addresses an unmet clinical need for patients with hematological malignancies; NiCord, a graft of stem/progenitor cells for hematological, autoimmune, and metabolic diseases; CordB...
Nahum Hafzadi 5 Street
Founded in 1998
Key Executives for Gamida Cell Ltd.
Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Vice President of Research & Development
Head of the Stem Cell Consortium Projects
Compensation as of Fiscal Year 2017.
Gamida Cell Ltd. Key Developments
Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
Jul 10 17
Gamida Cell announced that Ronit Simantov, M.D. will join the company as its new Chief Medical Officer (CMO) based in the U.S. Prior to joining Gamida Cell, Dr. Simantov was Vice President and Head of Global Medical Affairs at Pfizer Oncology. Previous roles included Vice President, Head of Clinical Development at OSI Pharmaceuticals, Chief Medical Officer at CuraGen Corporation, and Global Clinical Leader in Oncology at Bayer HealthCare Pharmaceuticals.
Gamida Cell Ltd. Announces $40 Million Private Financing
Jun 19 17
Gamida Cell Ltd. announced the signing of a $40 million financing to support the ongoing Phase 3 trial of the company's FDA Breakthrough Designated clinical-stage product, NiCord, to facilitate bone marrow transplantation. The financing is being led by new investor Shavit Capital. Additional primary participants include new investors VMS Investment Group and Israel Biotech Fund, as well as existing investor and major shareholder, Novartis. Current shareholders Clal Biotechnology Industries (CBI) and Israel HealthCare Ventures (IHCV) also participated in the financing. Gamida Cell plans to use the proceeds to complete NiCord's Phase 3 clinical trial and prepare for product commercialization by expanding its in-house manufacturing capacity, and the Company's presence in the US, as well as continuing to develop additional pipeline products such as CordIn ® for rare genetic diseases and NK cells as a treatment for cancer.
Gamida Cell Announces Appointments to its Board of Directors
Jun 5 17
Gamida Cell announced the appointment of Nobel Prize Laureate Professor Roger Kornberg and immune oncology expert and recently retired Novartis executive Dr. Michael Perry to its Board of Directors. Dr. Michael Perry recently retired from Novartis, following a highly successful tenure where he served as SVP and Chief Scientific Officer, Global BD&L, Chief Scientific Officer, Cell & Gene Therapy Unit, Global Head, Cellular Therapy/VP, Integrated Hospital Care Franchise and as Novartis' observer on the Gamida Cell Board of Directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 19, 2017
March 5, 2017